Thursday, October 18, 2012
Cell therapy for liver disease typically involves delivery of
hepatocytes to the liver intraportal vein, which carries a risk of hemorrhage,
elevated portal pressure and portal vein thrombosis. Now, a University of Pittsburgh School of Medicine team
thinks it has found a better delivery route-the lymph nodes. The team has mouse
data demonstrating that transplantation of cells into lymph nodes led to
generation of ectopic tissue that exhibited liver function,1 and the
group is testing the approach in pig models of liver failure.
Going to the
T. SciBX 5(41);
Published online Oct. 18, 2012
1. Komori, J. et al.
Nat. Biotechnol.; published online Sept. 23, 2012; doi:10.1038/nbt.2379
Contact: Eric Lagasse, University of Pittsburgh School of Medicine,
2. Hoppo, T. et al.
Gastroenterology 140, 656-666 (2011)
3. Lo, C.-M. et al.
Transplantation 68, 1112-1116 (1999)
Albert Einstein College of Medicine of Yeshiva University, New York, N.Y.
McGowan Institute for Regenerative Medicine, Pittsburgh, Pa.
Memorial Sloan-Kettering Cancer Center, New York, N.Y.
Tengion Inc. (OTCQB:TNGN), Winston-Salem, N.C.
University of Pittsburgh School of Medicine, Pittsburgh, Pa.